Cargando…
Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors
Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D) in clinic. Previous studies have shown linagliptin improves β cell function using animal models and isolated is...
Autores principales: | Zhang, Yanqing, Wu, Meifen, Htun, Wynn, Dong, Emily W., Mauvais-Jarvis, Franck, Fonseca, Vivian A., Wu, Hongju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554162/ https://www.ncbi.nlm.nih.gov/pubmed/28801559 http://dx.doi.org/10.1038/s41598-017-08271-9 |
Ejemplares similares
-
Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice
por: Zhang, Yanqing, et al.
Publicado: (2017) -
Sex differences in metabolic homeostasis, diabetes, and obesity
por: Mauvais-Jarvis, Franck
Publicado: (2015) -
Erratum. GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner. Diabetes 2019;68:34–44
por: Zhang, Yanqing, et al.
Publicado: (2020) -
Is Estradiol a Biomarker of Type 2 Diabetes Risk in Postmenopausal Women?
por: Mauvais-Jarvis, Franck
Publicado: (2017) -
Sex differences underlying pancreatic islet biology and its dysfunction
por: Gannon, Maureen, et al.
Publicado: (2018)